Member Info for hahahehehoho

Selling is for Novacyt which I did do reluctantly this morning. Selling does not apply to next generation POC stocks , and deeply I suspect Paraytec will be heavily involved globally as they will be able diagnose how far along the infection is and be able quarantine accordingly. All this with a result and diagnostic analysis within seconds by Paraytec.....

You need to remember, PCR isn't going to be around for much longer as they have done nothing to ease the curve, and governments will soon realize this and be collectively spending hundreds of billions on POC at the start of 2021.....

75, This board is very respectable and mature right now. I think I can understand winner is worried this may change after Friday. I can see where he is coming from!

winner, makes no difference what dates are given or when people jump on board or what people write on LSE because if the company has innovative products coupled with sales / marketing led by a really dynamic CEO, the company will succeed no matter what.. BTW, Novacyt was full of people jumping on board at 100p for several weeks with multiple idiots on LSE writing nonsense.....

75, thanks for your reply, If they have been developing PCR as you say and point of care for 6 months with a truck load of cash then I'm definitely not touching that. Makes me realize just how lucky I am to be invested here with talented people.

rr ,from what i see from gdr's accounts is that they have had 9 million in funding , spent all of last years remaining money (£3.5 million already) and yet to develop a POC test within 30 mins. iphonetrader is the person to ask really as he seems to be a holder. I also assume that GDR have a larger workforce than Paraytec, and BRH have never had anything near that kind of funding or time yet appear initially to achieved some kind of success.
As I said before, it is not the amount of cash you throw at a project , in this industry it is the quality of the people you employ which determines the company's success. Apple was initially founded by two people and zero cash a the bank remember ;-)

Useful twitter link. I also note Jon Deeks has retracted his statement on Abingdon Health (and ODX) and never gave a reason why . You can also see he has left his original tweets up and not deleted it,. This is probably because Abingdon and the University of Birmingham have formed a partnership and I assume he doesn't want to lose his job. It could also be that he has had defamation letters from Abingdon or ODX's lawyers.

Wilson63, it seems that iphonetrader knows exactly what he is talking about. He has more knowledgeable depth on the company it seems. All I i know is that they have had the cash and development time for POC for almost 6months (?) and cannot get it under 30 minutes. My comparison to GDR's market capital was never originally started by me, I just used somebody elses example here but they are correct as market valuations on COVID stocks are vast and sometimes puzzling.

BTW POC coincidentally has 2 meanings here :-)

I think you can forget GDR from a future technological point of view because they seem to be months behind us in terms of POC. DVRG/SKIN don't have any IP and a very flawed breathalyzer testing system but due to similar market capital comparisons between the two, you may be correct in stating as 60m for BRH.
IF successful on Friday you could compare BRH to TTG and BRH in terms of m cap. A big IF though....but exciting.

PL75, I wouldn't rule TTG completely out, especially with Heathrow about to put in some very large orders. In this case we are not talking PCR but just optical and AI technology. New technology often does have its critics as always.

Nonetheless, BRH get the best of both worlds as our tests are two stage using biochemistry and cutting edge optical technology. If successful on Friday who knows where will be ;-p

smacks, I would probably compare Paraytec's test on par to Avacta's and TT electronics' one. In fact TT just completed their Proof of Concept idea a few weeks ago and the overconfident RNS added 220 millions pounds to its market cap.

Nonethelesss , BRH, TTG, AVCT are all on the same level but at different stages.

Rocky500, I don't think any other company test including Avacta's could tell what stage of infection a person is in . Paraytec's machine seems to be able to detect concentration levels (protein bind spikes as per time) and I did put up a post stating quarantine days could be customized as per patient. Instead of a two week isolation period a patient could be given two days. This benefits everyone, economy, insurance companies, employers. This could be a very important global machine.

- People are making millions selling substandard masks globally. Once it becomes compulsory in the UK to wear masks , BRH stands to benefit . Remember the NHS is the fourth largest employer in the world and this is a UK company, So I'd expect 5million to be produced some point in 2021. However the revenues of masks will pale in significance to what the tests will bring.
- CAPTURE and SIGNAL seems to be self developed pregnancy style type test not dissimilar to the Avacta one they are developing. More details will be shed on after Friday, and this is extremely exciting
- The light detector is not the large one as pictured on the Paraytec homepage. The one used will be size of an old camera and extremely easy to operate. This will be used in conjunction with Capture and Signal for further thorough COVID tests.
- Varying tests times have been bandied around on here. If you have the virus and concentrations are high, it can literally take a couple of seconds to diagnose and detect.
- Comparisons with other COVID stocks are wrong. Think, Novacyt as a big Great White shark, with ODX, GDR, EDF and co as crabs picking up their leftovers. Think BRH and AVCT as blue whales which are waiting above and yet to eat in 2020.
- I was tempted to sell Novacyt last week. But I am now certain I'll sell sometime next week and pile it on here.

As always DYOR

Never thought selling masks (in which BRH own a 50% stake in P2f) would represent 15% of our company. People might as well sell down to 5p, because there appears to be no limit and today was ridiculous. Once people realize we have a test not that dissimilar to Avacta's in development I'm sure we shall look back on this day in laughter!!!! Meanwhile any guesses for SP opening tomorrow? 25p?!

I'd also like to add antiviral nanotech masks do not cost 99p each. I'd assume they cost a lot more.

Nothing makes sense on AIM Shear. Very happy to off topped up.

Finally topped up, extremely happy. This is good news, initial orders are looking very good and masks are just a sideshow for us remember.

Initial order of a million nanotech masks a month. Delay, sure, but that is huge for a 12 million mark cap company.

I'd also like to add, after reading Prof Smythe's tweets that CAPTURE is theoretically transferrable to a paper test but the drawback is that sensitivity is diminished.

- Avacta Have their own pregnancy style 10 min tests charged at £25 set to be launched in 2021
- Sona Nanotech have a similar 5-15min test priced $50 set tobe launched in 2021
- Deepverge aka Integumen have an instant test costing £4 a chip, plus £20 for breathalyzer , plus £x for replacement mist cannister and needs to be charged. And reading machine would cost a few thousand pounds initially and is set to be launched in 2021
Paraytec alone with CAPTURE probably has the same abilities as the first 2 points above but together with a reading machine has the the additional ability of the third point. All costs unknown yet.

Despite being "late" , I'd also like to add Paraytec have done this on a minimal budget, whereas, most other companies have placed or borrowed millions. For science and technology, it just goes to show, sometimes it's not the amount of money you throw at developing a product, it's all the about the talent and quality of people you employ.

I think the fact that someone on Twitter has asked Professor Smythe how Paraytec's Aptamer based CAPTURE and SIGNAL test vs Avacta's Affimer-based point-of-care rapid test compares tell you all need to know. This is reaffirmed with his answer that clinical trials need to be run to compare the two says everything that they could be on the same level. If anyone uses their common sense nothing really more needs to be said with regards to where the SP could be if all is successful.